Centogene (NASDAQ:CNTG) will release its earnings data before the market opens on Wednesday, November 24th. Analysts expect Centogene to post earnings of ($0.59) per share for the quarter.
Centogene (NASDAQ:CNTG) last issued its quarterly earnings data on Monday, September 6th. The company reported ($0.37) EPS for the quarter, missing analysts’ consensus estimates of ($0.26) by ($0.11). The firm had revenue of $62.49 million during the quarter, compared to analyst estimates of $38.53 million. Centogene had a negative return on equity of 25.39% and a negative net margin of 6.88%. On average, analysts expect Centogene to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.
Shares of Centogene stock opened at $9.16 on Friday. The firm has a market cap of $181.92 million, a PE ratio of -11.04 and a beta of -2.11. Centogene has a 1 year low of $8.61 and a 1 year high of $14.00. The firm’s 50-day simple moving average is $10.10 and its 200-day simple moving average is $10.39.
Several research analysts have commented on CNTG shares. Zacks Investment Research upgraded shares of Centogene from a “strong sell” rating to a “hold” rating in a research report on Tuesday, November 9th. Robert W. Baird upped their price target on shares of Centogene from $13.00 to $15.00 and gave the company an “outperform” rating in a research report on Wednesday, September 8th. One analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. According to data from MarketBeat.com, Centogene presently has an average rating of “Buy” and an average price target of $17.80.
Centogene Company Profile
Centogene N.V., together with its subsidiaries, focuses on rare diseases that transforms real-world clinical and genetic, or other data into actionable information for patients, physicians, and pharmaceutical companies worldwide. The company develops rare disease platform, a data repository, which includes epidemiologic, phenotypic, and heterogenetic data that enhances methods for identifying and monitoring rare hereditary diseases and provide solutions that accelerate the development of orphan drugs.
Featured Article: Forex
Receive News & Ratings for Centogene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Centogene and related companies with MarketBeat.com's FREE daily email newsletter.